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Dr Seipeltdoi:10.1016/j.jtcvs.2004.12.040Objective: Vascular remodeling, often accelerated after cardiovascular procedures,
may result in stenosis or aneurysm formation. The bone-associated protein os-
teopontin has been suggested to be involved in vascular remodeling, yet the effect
of locally applied osteopontin in an acute vascular injury model of aortic calcifi-
cation has not been examined.
Methods: Vascular healing of rabbit thoracic aortas treated locally with recombinant
osteopontin (dose: 1 g; n  16) or albumin (control, n  16) after acute injury
created by end-to-end anastomosis was evaluated. Matrix metalloproteinase-2 level
was quantified by gelatin zymography. Proliferation of smooth muscle cells was
detected by immunostaining for proliferative cell nuclear antigen.
Results: Osteopontin-treated aortas showed significantly diminished vascular re-
modeling with less calcification (P  .001) and reduced anastomotic luminal
stenosis (4% vs 28%, P  .002) compared with controls 2 months postsurgery.
Moreover, osteopontin-treated aortas revealed a thickened adventitia with increased
fibrosis (P  .006). Matrix metalloproteinase-2 level was up-regulated 2-fold with
osteopontin treatment compared with control at 1 week, returning to baseline by 1
month. Staining for proliferation cell nuclear antigen disclosed an increase in
proliferation cell nuclear antigen-positive smooth muscle cells in the media of
osteopontin-treated aortas at 1 week, normalizing by 1 month.
Conclusions: These data suggest a beneficial effect of locally applied osteopontin
after acute injury possibly by altering matrix metalloproteinase-2 activity and
smooth muscle cell proliferation. Brief application of osteopontin may effectively
enhance vascular healing by reducing calcification and thus maintaining luminal
integrity. The role of the osteopontin-related increase in adventitial fibrosis on
vascular healing has to be explored.
Vascular remodeling can result in vascular obstructive disease,1 often ac-companied by pathologic calcification or vascular aneurysmal disease asobserved in bicuspid aortic valve disease and Marfan syndrome.2 These
structural changes of the arterial wall often develop or are accelerated after cardio-
vascular surgical or interventional procedures, and therapeutic options to halt this
disease are limited. We recently reported that in an experimental rabbit model,
which simulates cardiovascular surgical interventions, recombinant vascular endo-
thelial growth factor protected the aorta from pathologic remodeling and calcifica-
tion,3 possibly by up-regulating vascular osteopontin (OPN) levels in the early phase
after arterial injury.4
OPN, a multifunctional acidic phosphoprotein normally expressed in mineralized
tissues such as bone and teeth, as well as in kidney,5 is present in uninjured arteries
at a low level but is expressed abundantly in injured arteries,4,6 suggesting a role in
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levels of OPN have been observed at sites of dystrophic
calcification in human atherosclerotic plaques and calcified
aortic valves.7-9 An in vitro study10 using vascular smooth
muscle cells (SMCs) and a study11 using OPN knockout
mice (OPN-/-) implied that the up-regulation of OPN has a
protective role to limit vascular calcification. In contrast,
other studies support a pathologic role of OPN as an inducer
of vascular SMC proliferation and migration,12 thus con-
tributing to an increase in medial thickness and neointimal
hyperplasia after cuff-induced injury.13 Carotid artery liga-
tion in OPN-null mice14 and neutralizing antibodies di-
rected against OPN after endothelial denudation diminished
neointimal formation.15 These apparent opposing actions
suggest that context and timing of OPN expression could be
important determinants of whether OPN acts as an inducer
or inhibitor of vascular remodeling.
Matrix metalloproteinases (MMPs) appear to be inti-
mately involved in vascular remodeling by degrading ex-
tracellular matrix, and their activity is up-regulated in a
wide spectrum of vascular diseases including aortic aneu-
rysm formation16,17 and Kawasaki disease,18 as well as
atherosclerotic plaque formation19 and intimal hyperplasia
after acute injury.20,21 MMPs can exert several actions on
the vessel wall, some of which involve OPN. Stimulation of
SMCs with OPN has been shown to increase MMPs,22 and
aortas of mice overexpressing OPN demonstrate elevated
MMP-2 and MMP-9 levels compared with wild-type
mice.13
In the present study we used our experimental rabbit
model, which simulates cardiovascular surgical interven-
tions prone to failure because of accelerated vasculopathy
including medial calcification,3 to determine the effect of
recombinant OPN, locally applied at the time of acute
arterial injury, on vascular remodeling. We hypothesized
that topically delivered OPN may diminish vascular calci-
fication and thus enhance healing of aortic end-to-end anas-
tomosis with reduced vascular stenosis.
Methods
Acute Aortic Injury Model
Thoracic aortic injury was performed on 32 male New Zealand
White rabbits (9 weeks old, mean weight 2.5  0.3 kg) as previ-
ously described.3,4 Briefly, the thoracic aorta was dissected free
just below the left subclavian artery in anesthetized rabbits. After
proximal and distal crossclamping, a 10-mm (confirmed by mea-
surement) ring of thoracic aorta was resected. This was followed
by an end-to-end anastomosis with the 7-0 Prolene running suture
technique (tension model). After surgery, the rabbits were allowed
to recuperate; they were maintained under standardized conditions
with a regular day and night cycle (12/12 hours), and free access
to water and standard rabbit diets (Hi-Fiber 5P25, Prolab, PMI
Nutrition International, St Louis, Mo). All animal experiments
were performed with approval of the Animal Care and Use Com-
mittee of Children’s Memorial Institute of Education and Research
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Laboratory Animals” (National Institutes of Health publication
No. 85-23, revised 1996).
Osteopontin Treatment
Treatment consisted of applying either 1 g of recombinant mouse
OPN (R&D Systems, Minneapolis, Minn) or the vehicle phosphate-
buffered saline and 0.1% albumin as control to the intraluminal
surface, while performing the anastomosis (10 minutes exposure
time), and to the serosal surface (1 mm beyond the crossclamps), for
10 minutes after finishing the anastomosis, by using a 1-mL syringe
with a 27G needle (Sherwood Medical) to drip 0.2 mL of solution to
the intraluminal and serosal surfaces. At no time did the needle make
contact with the vessel wall.
Histology and Morphometry
At postoperative time intervals of 1 day (n  4), 1 week (n  8),
1 month (n  10), and 2 months (n  10), equal numbers of
control and OPN-treated animals were weighed and sacrificed. The
aorta was transected longitudinally, the inner circumference was
measured at the anastomosis and 1 cm proximal and distal to the
anastomosis, and the internal diameter and luminal area were
calculated as described.3 The relative area change assessed at the
anastomotic site compared with the area 1 cm proximal to the site
was calculated. For histologic examination, the proximal segment
of the anastomotic area was divided into 3 equal sections: the
anastomosis itself, the portion including the proximal crossclamp,
and the aortic wall between the anastomosis and the crossclamp.
Parallel sections from each group were assessed, and a mean score
was calculated for each aorta using values obtained from all 3
segments. In addition, a segment 1 cm distal to the anastomosis
was examined. The tissue was fixed in 10% formalin overnight.
The aorta adjacent to the anastomotic suture line up to and includ-
ing the distal crossclamp area was snap-frozen in liquid nitrogen
and stored at 80°C. The formalin-fixed tissue was processed and
embedded in paraffin, and 4-m sections were placed on a glass
slide and stained with hematoxylin-eosin, elastica van Gieson, and
Von Kossa stains. The degree of fibrosis and calcification was
graded 1 to 4 (1  none; 4  severe) by a pathologist (S.E.C.)
blinded to treatment regimen as previously described.3,4
Medial thickness and thickness of adventitial fibrosis were
measured at 4 positions on each of 3 histologic sections per aorta.
The first position was randomly chosen, and the others at approx-
imately 45°, 90°, and 135° around the vessel perimeter23; the
average of the 12 measurements was taken per animal as the mean
thickness. The external aortic diameter, with the border of adventitial
fibrosis-surrounding tissue as the outer limit, was calculated at the
anastomosis and 1 cm proximal and distal to the anastomosis.
Immunohistochemistry
Paraffin-embedded aortic sections were immunostained using an
antibody directed against proliferating cell nuclear antigen
(PCNA; Dako, Carpinteria, Calif). Sections were dried at 42°C for
24 hours, deparaffinized, incubated at room temperature with the
primary antibody, incubated with an avidin-biotin peroxidase con-
jugated secondary antibody, and counterstained with hematoxylin.
Those cells exhibiting a brown color were scored positive. At least
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P1000 SMCs were counted in each aorta, and the percentage of
SMCs with positive PCNA staining was calculated.
Gelatinase Zymography
Collagenase IV (gelatinase) activity in both the control and OPN-
treated thoracic aortas was determined by zymography with 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis con-
taining 0.1% gelatin (1 mg/mL, Sigma, St Louis, Mo) as described
elsewhere.17,19 Briefly, the snap-frozen aortic tissue was homog-
enized in radioimmunoprecipitation (RIPA) buffer, and the protein
concentration was determined by protein assay (Bio-Rad, Her-
cules, Calif). Equal amounts of protein (30 g) were mixed with
sample buffer and electrophoresed under nonreducing conditions.
Figure 1. Local recombinant OPN altered aortic healing
calcification but increased adventitial fibrosis. Aort
postinjury. A and B, Hematoxylin-eosin staining. Contro
OPN-treated aortas had minimal medial pathology. In
heads). The dystrophic calcification disrupted the integ
fibrosis of OPN-treated aortas. C and D, Elastica van G
control and OPN-treated aortas. Note alteration in e
Osteopontin; A, adventitia; M, media; L, lumen.After electrophoresis, sodium dodecyl sulfate was eluted from the
The Journal of Thoracigel in 2.5% Triton X-100 for 30 minutes at room temperature. The
gels then were incubated in 50 mmol/L Tris-HCl, pH 8.0, 0.2
mol/L NaCl, 5 mmol/L CaCl2, and 0.02% Brij 35 at 37°C for 16
hours. After the gel was stained with Coomassie blue R-250,
gelatin-degrading enzymes were identified by their ability to clear
the substrate at their respective molecular weights. Gels were
calibrated with molecular weight markers (Bio-Rad). Each sample
was quantified by densitometric methodology.
Statistical Analysis
Results are expressed as mean  SEM. Statistical differences
between nominally and ordinally scaled variables were determined
with the chi-square test. Continuous variables were analyzed with
r end-to-end anastomosis with significantly diminished
ctions were adjacent sections harvested 2 months
ealed a region of dystrophic calcification (*), whereas
ce between calcific deposit and media (open arrow-
f the vascular media. Note the increase in adventitial
n staining. Comparable medial thickness was seen in






lasticthe unpaired 2-tailed Student t test and analysis of variance.
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Effect of OPN on Vascular Calcification
Control and OPN-treated rabbits had similar postoperative
courses with comparable percentage gain in total body
weight 2 months after surgery. Histologically, the control
aortas revealed marked remodeling within 1 week, and these
pathologic findings progressed with time. By 1 and 2
months postopertively (Figure 1, A, C), all controls showed
band-like regions of dystrophic medial calcification deter-
mined by von Kossa staining (data not shown). In striking
contrast, OPN treatment resulted in a distinct pattern of
vascular remodeling at all time points. At 2 months post-
operatively, medial calcification was significantly reduced
compared with controls (P  .001, Table 1), and in 3 of 5
OPN-treated aortic specimens islands of calcification were
absent in all 3 sections taken for histology (Figure 1, B, D).
In 2 aortic specimens, there was focal calcification at the
suture line only.
Adventitial Fibrosis and Anastomotic Luminal Stenosis
An unexpected finding of our experiments was the signifi-
cant increase in adventitial fibrosis in OPN-treated aortas
TABLE 1. Difference in vascular medial calcification and
adventitial fibrosis between control (n  15 histologic
sections; three sections/aorta) and osteopontin-treated
(n  15) aortic specimens two months postinjury (medial
calcification P < .001; adventitial fibrosis P  .004)












TABLE 2. Morphologic features of the aortic wall two







Luminal area stenosis (%) 28.2 4.9 4.1 1.7 .002
Medial thickness (m) 284  16 307 14 .31
Thickness of adventitial
fibrosis (m)
148 11 246 17 .001
Vessel wall thickness (m) 428 14 553 29 .005OPN, Osteopontin.
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of adventitial fibrosis increased in OPN-treated aortas com-
pared with controls by 1 week, and these morphologic
differences became even more apparent by 2 months post-
operatively (Table 2, Figure 1, A, B). However, this mor-
phologic change did not impinge on the vascular lumina. By
2 months postoperatively, the internal diameter at the anas-
tomosis with OPN treatment was significantly greater com-
pared with controls (mean internal diameter: 4.3  0.3 mm
in OPN-treated aorta vs 3.7  0.4 mm, P  .03). OPN
treatment significantly diminished the luminal stenosis at
the anastomotic site to only 4%, whereas the control group
specimens revealed a luminal stenosis of 28% (P  .002,
Table 2). Furthermore, the control aortas revealed a signif-
icantly diminished external diameter at the anastomosis
compared with 1 cm proximal because of the reduced in-
ternal diameter, and thus luminal area (Table 3).
Matrix Metalloproteinases
A gelatinolytic band at 72 kDa, corresponding to the latent
form of MMP-2, was present in both groups at all time
points (Figure 2, A). Densitometric quantification indicated
an increase in latent MMP-2 in OPN-treated aortas com-
pared with controls at 1 week, returning to baseline by
1 month. A second gelatinolytic band at 62 kDa revealed the
activated form of MMP-2. In both groups, there was a rapid
increase in activated MMP-2 by 24 hours, peaking at
1 week. OPN induced a transient increase in MMP-2 re-
vealing a 1.9-fold up-regulation in activated MMP-2 com-
pared with control at 1 week (P .001) and a return to time
0 levels by 1 month, whereas activated MMP-2 was more
chronically elevated with a persistent increase in the control
aortas (Figure 2, A, B). At 24 hours, lesser intensity bands at
92 and 80 kDa (most likely representing pro-MMP-9 and its
activated form)24 appeared in the OPN treatment group,
whereas the control group revealed a pro-MMP-9 band
only. MMP-9 levels returned to baseline by 1 week in both
groups.
SMC Proliferation
Because OPN is known to promote vascular SMC proliferation
in vitro12,25 and in mice overexpressing OPN,13 we determined
whether there was an alteration of medial SMC proliferation
after brief exposure to OPN in our model. The pattern of SMC
proliferation was different between the 2 groups. By 1 week
postoperatively, the OPN-treated aortic media showed a sig-
nificant increase in PCNA-positive SMC nuclei (Figure 3, B,
inset), in contrast with the only rare positive staining SMC
nucleus in the control aortas (Figure 3, A). By 1 month, the
SMC proliferation in OPN-treated aortas diminished to levels
seen in control aortas (Figure 3, C). Although there appeared to
be an OPN-mediated increase in SMC proliferation when the
medial thickness was measured, the control and OPN-treated
st 2005
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Paortic media were comparable 2 months postoperatively (Table
2). Moreover, the mean number of elastic lamellae was similar
in both groups when avoiding the band-like regions of calci-
fication in the control aortas (Figure 1, C, D; mean number of
elastic lamellae 20.9  0.6 in controls vs 21.4  0.5 in
OPN-treated aortas, respectively). In these regions of the con-
trol aortas, elastic lamellae were replaced by calcification and
thus reduced. Intimal proliferative lesions were not observed in
the control or the OPN-treated aortas at any time point.







Figure 2. Representative zymograms for pro-MMP-2 an
showing increased MMP-2 level at 1 week in OPN-tre
B, corresponding densitometric analysis of the activat
with control group. OPN, Osteopontin; MMP, matrix metall
The Journal of ThoraciDiscussion
To our knowledge, this is the first in vivo study to show that
a single dose of recombinant OPN applied at the site of an
acute arterial injury is capable of effectively suppressing
calcification and modulating vascular remodeling. Arterial
obstructive disease, often associated with pathologic calci-
fication, and vascular aneurysm disease are the result of
severe vascular remodeling contributing to a high rate of
morbidity and mortality. Recently, OPN, a bone-associated
s, and distal aorta two months postinjury
trol (n  5) OPN treated (n  5) P value
47 0.18 5.60 0.046 .543
77 0.28 5.65 0.10 .034
.5 0.13 5.54 0.06 .741
tivated MMP-2 and pro-MMP-9 and activated MMP-9
aorta (right, A) when compared with controls (left, A).






ed Moproteinase; 0, level at time 0.
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protein, has been implicated in vascular remodeling. Al-
though OPN-deficient mice showed no disturbance in vas-
cular calcification when crossed with matrix Gla protein-
null mice26 or Apo-E-null mice,27 they had increased levels
of arterial calcification. A hemodynamic study in OPN-null
mice demonstrated greater vascular wall compliance, sug-
gesting a regulatory role in normal vascular physiology.14
However, studies in OPN-overexpressing mice suggested
OPN to be involved in the development of atherosclerosis
and vascular stenosis because of intimal proliferation.13
These diverse actions of OPN on the vascular wall make it
difficult to predict whether a single dose of OPN, exog-
Figure 3. Immunohistochemical staining for PCNA of
postinjury revealed increased vascular smooth musc
nuclei (arrowheads). Inset in (B) demonstrates 2 PCN
resulted in a significant increase in the percentage of
mean  SEM. *P < .05 compared with control group. O
VSMC, vascular smooth muscle cell.enously delivered, has a beneficial or adverse effect on
360 The Journal of Thoracic and Cardiovascular Surgery ● Auguvascular healing after acute injury. To more directly assess
a potential therapeutic role of OPN on vascular remodeling,
and in particular on vascular calcification, we applied re-
combinant OPN locally at the site of aortic injury in an
acute arterial injury model.3 In this model we performed a
similar operation as in coarctation repair with excision of an
aortic ring and end-to-end anastomosis; however, the aortic
ring in coarctation repair is mainly ductal tissue. Our in vivo
data revealed that a single dose of OPN locally applied at
the time of arterial injury is capable of maintaining the
vessel lumen possibly by suppressing the development of
pathologic calcification. An unexpected finding occurred
rol (A) and OPN-treated aortas (B) harvested 1 week
ll (SMC) proliferation after OPN treatment. Positive
nuclei next to 1 negative nucleus. C, OPN treatment
s with positive PCNA staining by 1 week. Results are




PN,within the adventitial segment of the vessel. Adventitial
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Pfibrosis, determined by histologic grading and measure-
ments, was found to be significantly increased in OPN-
treated aortas compared with controls. Recent data suggest
that OPN may play a role in the development of tissue
fibrosis, because OPN is chemotactic for fibroblasts and
potentiates growth factor-mediated fibroblast prolifera-
tion.28,29 In the present study it is unclear whether the
OPN-related increase in adventitial fibrosis might be bene-
ficial to vessels prone to aneurysmal formation or might
alter the compliance of the vessel, resulting in enhanced
wall stress and early degeneration. Therefore, further stud-
ies with longer time intervals and a model of developing
aortic aneurysm are needed.
Our results indicate 2 other potential mechanisms under-
lying the ability of OPN to alter vascular remodeling when
exogenously applied at the time of injury. The first obser-
vation is related to rapid but transient up-regulation of
MMP-2 and activated MMP-9, and the second observation
involves transient increase of SMC proliferation. MMP-2, a
72 kDa type IV collagenase that degrades extracellular
matrix and basement membrane proteins (eg, collagen and
elastin) and that enhances SMC migration, is secreted from
a variety of cell types, including vascular endothelial cells
and SMCs.30 Several studies suggest that MMP-2 and
MMP-9 are involved in vascular remodeling associated with
vascular disease and injury, resulting in arterial obstructive
disease or aneurysm formation.16-21 Our data confirm the
involvement of MMP-2 and MMP-9 in vascular remodeling
because both were increased after arterial injury. Brief ex-
posure to OPN in this study was a trigger to more rapidly
but transiently up-regulate MMP-2 activity 2-fold compared
with control aortas with return to time 0 levels by 1 month.
The transient increase in MMP-2 may be beneficial in this
model to facilitate replacement of dead cell bodies that
occur after arterial injury within the media. This would be
consistent with the temporary increase in SMC proliferation
within the media of OPN-treated aortas. The role of elevated
MMP-2 at later time points in control aortas that develop
severe vascular remodeling needs to be clarified.
OPN treatment of the aorta has been shown to promote
SMC proliferation in vitro.12,25 A transgenic mice model
with chronic OPN overexpression developed a thickened
arterial media, and, after cuff-induced injury, intimal pro-
liferation was noted.13 In the current study, the brief expo-
sure of OPN induced an early increase in SMC prolifera-
tion; however, this was only a transient activity because the
number of PCNA-positive SMCs returned to baseline by 1
month. The medial thickness remained unchanged when
compared with control animals, and intimal proliferative
lesions were not observed. These results suggest that the short
exposure time to OPN after arterial injury may be crucial for its
beneficial action, whereas chronic exposure to OPN appears to
be associated with deleterious consequences.13
The Journal of ThoraciLimitations
This study was performed to determine a possible role of
exogenously added OPN on vascular healing as suggested
by a previous study performed in our laboratory.4 However,
at this point we do not know the ideal OPN concentration to
promote the best vascular healing. Therefore, the optimal
OPN concentration and exposure time will need to be de-
fined in future experiments. Furthermore, we do not know
whether intraluminal or adventitial exposure alone is more
or less effective on the reduction of medial calcification or
adventitial fibrosis. Second, this study only measured iso-
lated metalloproteinase levels ex vivo with zymography.
However, the balance of MMPs and their natural inhibitors
are important to determine their activity.
In summary, the present study demonstrated that a brief
local OPN exposure might be effective to induce a response
within the injured arterial wall. OPN was capable of pro-
tecting the arterial wall from pathologic vascular remodel-
ing probably by, directly or indirectly, reducing calcifica-
tion, rapidly up-regulating MMP-2, and increasing SMC
proliferation. The role of the OPN-related increase in ad-
ventitial fibrosis on vascular healing has to be explored.
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